Search Results 11-20 of 17163 for egfr

  1. Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations - Mayo Clinic

    ... (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma multiforme (GBM) expressing EGFR alterations ...

  2. Partial nephrectomy associated with lower rates of chronic kidney disease stage progression - Mayo Clinic

    Furthermore, progression from a lesser stage to CKD stage 3B or higher (eGFR < 45 mL/min/1.73m2) has been associated with increased cardiovascular events and ...

  3. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

    A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) ...

  4. Creatinine test - Mayo Clinic

    Creatinine with estimated glomerular filtration rate (eGFR), serum. Mayo Clinic Laboratories. https://www.mayocliniclabs.com/test-catalog/overview/48216 ...

  5. TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

    TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell ...

  6. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration - Mayo Clinic

    Clinical Trials · Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration · More about research at Mayo Clinic · Mayo Clinic ...

  7. A Study Of BH-30643 In Subjects With Locally Advanced Or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations - Mayo Clinic

    Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the ...

  8. A Study of the Safety and Effectiveness of INC280 Alone and in Combination with Erlotinib, When Compared to Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutation and Amplified cMET - Mayo Clinic

    ... EGFR mutated and cMET amplified advanced/metastatic non-small cell lung cancer,and have acquired resistance to prior EGFR tyrosine kinase inhibitors.

  9. Osimertinib (oral route) - Side effects & dosage - Mayo Clinic

    ... EGFR tyrosine kinase inhibitor (TKI) treatment, which did not work. Your doctor will perform a test to check for the EGFR gene before you use this medicine.

  10. Pulmonary Medicine - Clinical trials

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...